Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of FLUAD MF59C.1-adjuvanted influenza vaccine in elderly subjects (2006-2007 formulation)
2006-000610-20Phase 2Completed
- Sponsor
- Chiron Corporation
- Start
- Jul 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Fluzone Trivalent in influenza, sponsored by Chiron Corporation. Primary endpoints: Immunogenicity by SRH at 21 days post-immunization and Safety of single intramuscular FLUAD injection. Started Jul 2007; status: completed.
02
Drugs
Fluzone Trivalent
03
Conditions
influenza
Beyond the preview
Go deeper on 2006-000610-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000610-20.